Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
J Psychosom Res ; 69(2): 151-9, 2010 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-20624513

RESUMO

OBJECTIVE: Previous research has suggested that the association between work stress and heart disease is more pronounced in young than in old employees. Similar age specificity may apply to the relation between work stress and heart rate variability (HRV), but data on this issue is sparse. We aimed to assess the age-specificity of the work stress-HRV association in greater detail. METHODS: We used cross-sectional data from an occupational cohort (n=591) from Germany. Work stress was assessed using the job content and the effort-reward-imbalance (ERI) questionnaires. HRV was recorded over 24 h and was divided into three periods of the day (work time, leisure time, sleep time). Partial correlation coefficients (PCCs) were calculated for four age groups (17-34, 35-44, 45-54, and 55-65 years). Further, multilevel growth curve models (GCM) were run to examine whether age may modify potential work stress-HRV associations in a non-linear fashion. RESULTS: Job strain and HRV were unrelated in either analytical approach and this association was not modified by age. In contrast, using PCCs ERI was only related to HRV during work (PCC=-0.231, P<.01) and leisure time (PCC=-0.195, P<.05) in employees aged 35-44. Multilevel GCM models confirmed this finding. CONCLUSION: The inverse association between work stress as measured by ERI and HRV appears to be most pronounced in workers aged 35-44. These findings may partly be explained by age-dependent HRV declines, age-related differences in career attitudes or increased susceptibility among those aged 35-44 due to facing multiple different stressors at the same time.


Assuntos
Nível de Alerta , Frequência Cardíaca , Satisfação no Emprego , Motivação , Recompensa , Estresse Psicológico/complicações , Adolescente , Adulto , Fatores Etários , Aeronaves , Estudos de Coortes , Estudos Transversais , Eletrocardiografia Ambulatorial , Feminino , Alemanha , Humanos , Indústrias , Masculino , Pessoa de Meia-Idade , Adulto Jovem
2.
Eur Arch Otorhinolaryngol ; 266(6): 919-25, 2009 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-18982338

RESUMO

Post-tonsillectomy swallowing pain is a common and distressing side effect after tonsillectomy and thus of great clinical interest. Up until now, there is no randomized controlled patient- and observer-blinded study evaluating the efficacy of acupuncture against swallowing pain after tonsillectomy. We therefore compared the potency of specific verum acupuncture points related to a Chinese medical diagnosis in reducing postoperative swallowing pain with non-specific control points on the body as well as a non-acupuncture group who received standard medication only. The standardized pain therapy after tonsillectomy was orally administered nonsteroidal anti-inflammatory drugs (NSAID) (diclofenac 3 x 50 mg oral). The patients (n = 123) treated with NSAID were asked about their acute pain after taking a sip of water between the first and fifth postoperative day. Participants' pain was assessed using visual analog (VAS) [zero (0) for no pain up to ten (10) for the acute reported outset pain] before and 20 min, 1, 2 and 3 h after acupuncture treatment or standard pain medication, respectively. The functional assessment of diagnosis and treatment point-combination occurred by means of the "Heidelberg Model" of Traditional Chinese Medicine (TCM). Verum acupuncture lead to a significant additional pain relief. In comparison to the acupuncture, they also reported an average of 3 h duration of adequate pain-relief past taking the NSAID. This trial strongly supports a specific acupuncture scheme for the treatment of postoperative swallowing pain after tonsillectomy. It may particularly serve as an alternative pain treatment in case of NSAID intolerances.


Assuntos
Terapia por Acupuntura/métodos , Anti-Inflamatórios não Esteroides/uso terapêutico , Dor Pós-Operatória/prevenção & controle , Tonsilectomia , Adolescente , Adulto , Humanos , Pessoa de Meia-Idade , Medição da Dor , Estudos Prospectivos , Tamanho da Amostra , Método Simples-Cego , Resultado do Tratamento
3.
Best Pract Res Clin Endocrinol Metab ; 17(4): 547-58, 2003 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-14687588

RESUMO

Hypophosphataemia does not necessarily indicate phosphate (Pi) depletion. In acute emergencies such as septicaemia, alkalosis or re-feeding, hypophosphataemia may result from redistribution of Pi from the extracellular to the intracellular space. Hypophosphataemia from true Pi depletion gives rise to skeletal (osteomalacia) and extraskeletal (myopathy, cardiomyopathy) disorders. It is practically never the result of diminished nutritional intake. The most severe syndromes of Pi depletion result from diminished tubular Pi re-absorption and renal Pi wasting. In the differential diagnosis mainly four conditions have to be considered: (i) tumour-associated osteomalacia, (ii) X-linked hypophosphataemia (XLH), (iii) autosomal dominant hypophosphataemia, and (iv) hypercalcaemic renal phosphate wasting. Recent molecular insight has put fibroblast growth factor (FGF-23) into the centre of pathophysiological considerations because of (i) overproduction (tumour-associated osteomalacia) or (ii) hypothetically, accumulation resulting from mutations causing resistance to processing or degradation (autosomal dominant hypophosphataemia) or (iii) loss-of-function of a protease (PHEX) interfering with FGF-23 breakdown (XLH). In oncogenic osteomalacia the treatment of choice is resection of the tumour. Recently, pharmacological treatment has also become possible, i.e. administration of octreotide. XLH and autosomal dominant hypophosphataemia must be managed by oral administration of phosphate and calcitriol. In patients with gastrointestinal intolerance to phosphate or with severely symptomatic bone disease, prolonged intravenous administration of Pi is necessary.


Assuntos
Hipofosfatemia Familiar , Hipofosfatemia , Fosfatos/metabolismo , Diagnóstico Diferencial , Fator de Crescimento de Fibroblastos 23 , Humanos , Hipercalcemia/complicações , Hipercalcemia/diagnóstico , Hipofosfatemia/etiologia , Hipofosfatemia/fisiopatologia , Hipofosfatemia/terapia , Hipofosfatemia Familiar/diagnóstico , Hipofosfatemia Familiar/metabolismo , Hipofosfatemia Familiar/terapia , Neoplasias/complicações , Neoplasias/diagnóstico , Osteomalacia/diagnóstico por imagem , Osteomalacia/metabolismo , Osteomalacia/terapia , Radiografia
5.
J Am Soc Nephrol ; 12(11): 2300-2309, 2001 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-11675406

RESUMO

Transforming growth factor-beta1 (TGF-beta 1) overexpression plays a key role in the glomerular accumulation of extracellular matrix proteins in renal disease. Retinoids have previously been shown to significantly limit glomerular damage in rat experimental glomerulonephritis. Therefore, the effects of all-trans retinoic acid and isotretinoin on the components of the TGF-beta system and extracellular matrix proteins in anti-Thy1.1-nephritis (Thy-GN) were investigated. Vehicle-injected control rats were compared with rats treated with daily subcutaneous injections of 10 mg/kg body wt all-trans retinoic acid or 40 mg/kg body wt isotretinoin (n = 9 per group) either with a pretreatment (day -2 through 8) or posttreatment protocol (day +3 through 8), i.e., starting before or after induction of Thy-GN, respectively. Urinary TGF-beta 1 excretion was 60% lower in all-trans retinoic acid-treated animals with Thy-GN (P < 0.025). The increase of cortical TGF-beta 1 gene expression in Thy-GN rats was significantly attenuated with all-trans retinoic acid and even more with isotretinoin treatment as compared with untreated animals (P < 0.025). Cortical expression of TGF receptor II, but not receptor I gene expression, was significantly lower in animals treated with all-trans retinoic acid or isotretinoin (P < 0.05). In all-trans retinoic acid-treated animals with Thy-GN, the increase of glomerular TGF-beta 1 protein (P < 0.008) and TGF-beta 1 (P < 0.025) and TGF receptor II mRNA (P < 0.015) was significantly less. Immunohistochemistry revealed less glomerular staining for TGF-beta 1 and TGF receptor II in the presence of all-trans retinoic acid. TGF-beta 1 immunostaining was not restricted to monocytes and macrophages, as indicated by double-staining. Glomerular staining for collagen IV and collagen III was less in animals treated with isotretinoin (P < 0.02 for both) in contrast to all-trans retinoic acid, whereas fibronectin remained unchanged. It was concluded that the beneficial effects of retinoids on glomerular damage are presumably due to a marked reduction in renal TGF-beta 1 and TGF receptor II expression.


Assuntos
Matriz Extracelular/efeitos dos fármacos , Glomerulonefrite/metabolismo , Retinoides/farmacologia , Fator de Crescimento Transformador beta/metabolismo , Animais , Anticorpos Monoclonais/administração & dosagem , Pressão Sanguínea/efeitos dos fármacos , Expressão Gênica/efeitos dos fármacos , Glomerulonefrite/imunologia , Isotretinoína/farmacologia , Córtex Renal/metabolismo , Glomérulos Renais/metabolismo , Masculino , Proteínas Serina-Treonina Quinases , RNA Mensageiro/metabolismo , Ratos , Ratos Wistar , Receptor do Fator de Crescimento Transformador beta Tipo II , Receptores de Fatores de Crescimento Transformadores beta/metabolismo , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Sístole , Antígenos Thy-1/imunologia , Fator de Crescimento Transformador beta/genética , Fator de Crescimento Transformador beta/urina , Fator de Crescimento Transformador beta1 , Tretinoína/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...